• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体-α-突触核蛋白复合物的结合稳定性预测抗-α-突触核蛋白抗体的保护效力。

Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.

机构信息

Department of Neurology, Hannover Medical School, Hannover, D-30625, Germany.

Department of Neurology, Technical University of Munich (TUM), D-81675, Munich, Germany.

出版信息

Mol Neurobiol. 2022 Jul;59(7):3980-3995. doi: 10.1007/s12035-022-02824-4. Epub 2022 Apr 22.

DOI:10.1007/s12035-022-02824-4
PMID:35460053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9167191/
Abstract

Spreading of alpha-synuclein (αSyn) may play an important role in Parkinson's disease and related synucleinopathies. Passive immunization with anti-αSyn antibodies is a promising method to slow down the spreading process and thereby the progression of synucleinopathies. Currently, it remains elusive which specific characteristics are essential to render therapeutic antibodies efficacious. Here, we established a neuronal co-culture model, in which αSyn species are being released from αSyn-overexpressing cells and induce toxicity in a priori healthy GFP-expressing cells. In this model, we investigated the protective efficacy of three anti-αSyn antibodies. Only two of these antibodies, one C-terminal and one N-terminal, protected from αSyn-induced toxicity by inhibiting the uptake of spreading-competent αSyn from the cell culture medium. Neither the binding epitope nor the affinity of the antibodies towards recombinant αSyn could explain differences in biological efficacy. However, both protective antibodies formed more stable antibody-αSyn complexes than the non-protective antibody. These findings indicate that the stability of antibody-αSyn complexes may be more important to confer protection than the binding epitope or affinity to recombinant αSyn.

摘要

α-突触核蛋白(αSyn)的扩散可能在帕金森病和相关的突触核蛋白病中发挥重要作用。用抗αSyn 抗体进行被动免疫是一种很有前途的方法,可以减缓扩散过程,从而减缓突触核蛋白病的进展。目前,尚不清楚使治疗性抗体有效的具体特征是什么。在这里,我们建立了一个神经元共培养模型,在该模型中,αSyn 物种从过表达 αSyn 的细胞中释放出来,并在前瞻性健康的 GFP 表达细胞中诱导毒性。在该模型中,我们研究了三种抗αSyn 抗体的保护效果。只有两种抗体,一种是 C 端的,一种是 N 端的,通过抑制从细胞培养基中摄取有扩散能力的 αSyn,从而防止 αSyn 诱导的毒性。抗体对重组 αSyn 的结合表位和亲和力都不能解释其生物学功效的差异。然而,两种保护性抗体形成的抗体-αSyn 复合物比非保护性抗体更稳定。这些发现表明,与结合表位或对重组 αSyn 的亲和力相比,抗体-αSyn 复合物的稳定性对于提供保护可能更为重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/003880cfe0d8/12035_2022_2824_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/d2a7dd346a69/12035_2022_2824_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/f1fb9b0f06d1/12035_2022_2824_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/38237fd43d94/12035_2022_2824_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/8405352e5316/12035_2022_2824_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/bf1c4908b721/12035_2022_2824_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/003880cfe0d8/12035_2022_2824_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/d2a7dd346a69/12035_2022_2824_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/f1fb9b0f06d1/12035_2022_2824_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/38237fd43d94/12035_2022_2824_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/8405352e5316/12035_2022_2824_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/bf1c4908b721/12035_2022_2824_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/535c/9167191/003880cfe0d8/12035_2022_2824_Fig6_HTML.jpg

相似文献

1
Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.抗体-α-突触核蛋白复合物的结合稳定性预测抗-α-突触核蛋白抗体的保护效力。
Mol Neurobiol. 2022 Jul;59(7):3980-3995. doi: 10.1007/s12035-022-02824-4. Epub 2022 Apr 22.
2
A charged tail on anti-α-Synuclein antibodies does not enhance their affinity to α-Synuclein fibrils.带电荷的抗α-突触核蛋白抗体的尾部不会增强其与α-突触核蛋白纤维的亲和力。
PLoS One. 2024 Aug 29;19(8):e0308521. doi: 10.1371/journal.pone.0308521. eCollection 2024.
3
Antibodies against alpha-synuclein: tools and therapies.抗α-突触核蛋白抗体:工具与疗法。
J Neurochem. 2019 Sep;150(5):612-625. doi: 10.1111/jnc.14713. Epub 2019 Jun 25.
4
A multiverse of α-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal models.α-突触核蛋白的多重宇宙:用羧基末端截断特异性抗体在动物模型中研究朊病毒株特性。
Acta Neuropathol Commun. 2024 Jun 10;12(1):91. doi: 10.1186/s40478-024-01805-z.
5
Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia.可溶性 α-突触核蛋白抗体复合物激活人诱导多能干细胞源性小胶质细胞中的 NLRP3 炎性体。
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15). doi: 10.1073/pnas.2025847118.
6
14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.14-3-3 蛋白减少致病性 α-突触核蛋白的细胞间转移和传播。
J Neurosci. 2018 Sep 19;38(38):8211-8232. doi: 10.1523/JNEUROSCI.1134-18.2018. Epub 2018 Aug 9.
7
Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.AAV-Alpha 突触核蛋白 NAC 抗体给药改善过表达 Alpha 突触核蛋白的大鼠的运动行为。
Genes (Basel). 2021 Jun 21;12(6):948. doi: 10.3390/genes12060948.
8
Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies.在突触核蛋白病中,α-突触核蛋白羧基末端截断的疾病、区域和细胞类型特异性多样性。
Acta Neuropathol Commun. 2021 Aug 28;9(1):146. doi: 10.1186/s40478-021-01242-2.
9
Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.针对α-突触核蛋白 C 端的肽免疫接种可降低过表达α-突触核蛋白的小鼠的运动活性。
PLoS One. 2023 Sep 21;18(9):e0291927. doi: 10.1371/journal.pone.0291927. eCollection 2023.
10
Sortilin acts as an endocytic receptor for α-synuclein fibril.Sortilin 作为α-突触核蛋白原纤维的内吞受体发挥作用。
FASEB J. 2023 Jul;37(7):e23017. doi: 10.1096/fj.202201605RR.

引用本文的文献

1
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.突触核蛋白病中的α-突触核蛋白病理学:机制、生物标志物及治疗挑战
Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405.
2
Parkinson's disease therapy: what lies ahead?帕金森病的治疗:未来的方向?
J Neural Transm (Vienna). 2023 Jun;130(6):793-820. doi: 10.1007/s00702-023-02641-6. Epub 2023 May 5.
3
Alpha Synuclein: Neurodegeneration and Inflammation.α-突触核蛋白:神经退行性变与炎症。

本文引用的文献

1
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.一项评估普拉西奈单抗治疗早期帕金森病安全性和有效性的II期研究(帕萨迪纳研究):原理、设计和基线数据
Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021.
2
Alpha-synuclein fragments trigger distinct aggregation pathways.α-突触核蛋白片段触发不同的聚集途径。
Cell Death Dis. 2020 Feb 3;11(2):84. doi: 10.1038/s41419-020-2285-7.
3
The pharmacology and therapeutic applications of monoclonal antibodies.
Int J Mol Sci. 2023 Mar 21;24(6):5914. doi: 10.3390/ijms24065914.
4
A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice.一种新型的靶向C型凝集素受体的基于α-突触核蛋白的帕金森疫苗在小鼠中诱导出强效免疫反应和治疗效果。
Vaccines (Basel). 2022 Aug 30;10(9):1432. doi: 10.3390/vaccines10091432.
单克隆抗体的药理学和治疗应用。
Pharmacol Res Perspect. 2019 Dec;7(6):e00535. doi: 10.1002/prp2.535.
4
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.高亲和力α-突触核蛋白抗体 MEDI1341 的临床前开发,该抗体能够进入大脑,隔离细胞外α-突触核蛋白,并减轻体内α-突触核蛋白的扩散。
Neurobiol Dis. 2019 Dec;132:104582. doi: 10.1016/j.nbd.2019.104582. Epub 2019 Aug 21.
5
Transmission of α-synuclein seeds in neurodegenerative disease: recent developments.α-突触核蛋白在神经退行性疾病中的传播:最新进展。
Lab Invest. 2019 Jul;99(7):971-981. doi: 10.1038/s41374-019-0195-z. Epub 2019 Feb 13.
6
Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons.多种刺激巨自噬的分子途径可保护人神经元免受α-突触核蛋白诱导的毒性。
Neuropharmacology. 2019 May 1;149:13-26. doi: 10.1016/j.neuropharm.2019.01.023. Epub 2019 Feb 4.
7
The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.α-突触核蛋白的朊病毒样传播:从帕金森病的体外到体内模型。
Ageing Res Rev. 2019 Mar;50:89-101. doi: 10.1016/j.arr.2019.01.012. Epub 2019 Jan 25.
8
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.开发一种聚集物选择性的、源自人类的α-突触核蛋白抗体 BIIB054,可改善帕金森病模型中的疾病表型。
Neurobiol Dis. 2019 Apr;124:276-288. doi: 10.1016/j.nbd.2018.10.016. Epub 2018 Oct 28.
9
Alpha-synuclein and the prion hypothesis in Parkinson's disease.α-突触核蛋白与帕金森病的朊病毒假说。
Rev Neurol (Paris). 2018 Nov;174(9):644-652. doi: 10.1016/j.neurol.2018.08.002. Epub 2018 Sep 7.
10
Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy.外泌体分泌的 α-突触核蛋白作为巨自噬上游阻断后的保护机制。
Cell Death Dis. 2018 Jul 9;9(7):757. doi: 10.1038/s41419-018-0816-2.